NCT03210337

A Phase2 of A-101 Topical Solution in Subjects With Common Warts

A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of A-101 Topical Solution Applied Once a Week in Subjects With Common Warts

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 157 (actual)
• Sponsor: Aclaris Therapeutics, Inc. · Industry
• Sex: All
• Age: 8 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of this study is to evaluate the effectiveness of A-101 compared to vehicle when applied to 1 common target wart on the trunk or extremities.

Detailed description

The primary objective of this study is to evaluate the effectiveness of A-101 compared to vehicle when applied to 1 common target wart on the trunk or extremities. The secondary objectives of this study are to evaluate the clinical effect of A-101 when applied to all treated warts (Target Warts plus Non-Target Warts), duration of response in all treated warts (Target Warts plus Non-Target Warts), and Safety of A-101.

Conditions

• Common Wart

Interventions

Type	Name	Description
DRUG	A-101 Topical Solution	A-101 Topical Solution
DRUG	A-101 Vehicle Solution	A-101 Vehicle Solution

Timeline

• Start date: 2017-08-01
• Primary completion: 2018-03-16
• Completion: 2018-03-16
• First posted: 2017-07-06
• Last updated: 2019-05-01
• Results posted: 2019-05-01

Locations

17 sites across 1 country: United States

Regulatory

• FDA-regulated drug study